Clinical Trial: Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888335) titled 'Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions' on Oct. 15.

Brief Summary: The goal of this clinical trial is to evaluate if obinutuzumab beta works to treat primary IgA nephropathy with active proliferative lesions in adults. It will also learn about the safety of obinutuzumab beta. The main questions it aims to answer are:

Does obinutuzumab beta reduce 24-hour urinary protein at Week 24 compared with baseline? Does obinutuzumab beta improve kidney function, reduce hematuria, and lower Gd-IgA1 levels? Does obinutuzumab beta change active lesionson repeat kidney biopsy at Week 5...